Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

35.43USD
22 Nov 2017
Change (% chg)

$-0.11 (-0.31%)
Prev Close
$35.54
Open
$35.45
Day's High
$35.50
Day's Low
$35.32
Volume
10,553,135
Avg. Vol
16,546,800
52-wk High
$36.78
52-wk Low
$30.51

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $211,843.50
Shares Outstanding(Mil.): 5,960.71
Dividend: 0.32
Yield (%): 3.60

Financials

  Industry Sector
P/E (TTM): -- 31.69 15.46
EPS (TTM): -- -- --
ROI: -- 15.18 11.85
ROE: -- 16.59 15.83

U.S. FDA approves first two-drug HIV regimen in win for GSK

The U.S. Food and Drug Administration has approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at lessening the side effect burden of current treatments that combine three or four medicines.

3:52am EST

UPDATE 2-U.S. FDA approves first two-drug HIV regimen in win for GSK

* Two-drug approach differentiates GSK from Gilead (Adds context on GSK drive to improve pharma sales)

3:46am EST

U.S. FDA approves first two-drug HIV regimen

NEW YORK, Nov 21 The U.S. Food and Drug Administration on Tuesday approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at easing the side effects for long-term patients who are on the standard treatment involving three or more drugs.

Nov 21 2017

FDA expands approval for Pfizer cancer drug Sutent

The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney.

Nov 16 2017

U.S. FDA expands approval for Pfizer cancer drug Sutent

Nov 16 The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney.

Nov 16 2017

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.

Nov 15 2017

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON, Nov 16 Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.

Nov 15 2017

Pfizer creates chief operating officer role for Bourla

NEW YORK Drugmaker Pfizer Inc has promoted Albert Bourla to the newly created post of chief operating officer, freeing up Chief Executive Officer Ian Read to focus more on long-term strategy and engaging with government and industry leaders.

Nov 13 2017

UPDATE 1-Pfizer creates chief operating officer role for Bourla

NEW YORK, Nov 13 Drugmaker Pfizer Inc has promoted Albert Bourla to the newly created post of chief operating officer, freeing up Chief Executive Officer Ian Read to focus more on long-term strategy and engaging with government and industry leaders.

Nov 13 2017

BRIEF-Pfizer names Albert Bourla chief operating officer

* Pfizer - ‍albert Bourla has been group president of co's innovative health business since beginning of 2016​

Nov 13 2017

Competitors

Earnings vs. Estimates